- Home
- BTE vs APLS Comparison
BTE vs APLS Comparison
Compare BTE & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTE | APLS |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Meat/Poultry/Fish | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.7B |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BTE | APLS |
|---|---|---|
| Price | $4.13 | $17.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $31.65 |
| AVG Volume (30 Days) | ★ 18.7M | 1.8M |
| Earning Date | 03-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.09 | $18.21 |
| P/E Ratio | ★ $18.43 | $89.68 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $1.36 | $16.10 |
| 52 Week High | $4.17 | $30.48 |
Technical Indicators
Market Signals| Indicator | BTE | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 69.89 | 27.58 |
| Support Level | $3.59 | $17.16 |
| Resistance Level | N/A | $20.42 |
| Average True Range (ATR) | 0.16 | 0.73 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 89.87 | 12.94 |
Price Performance
Historical ComparisonAbout BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.